2021 And 2022 Projected To Be Boom Years For Electromedical Technologies, Inc. (OTCQB: EMED) As Volume Seen Reaching $17+ Million In Market For The Bioelectronics Industry Treating Chronic And Acute Pain With Its WellnessPro Plus Device And WellnessPlus

2021 and 2022 may be boom years for Electromedical Technologies, Inc. (OTCQB: EMED) if analyst Goldman Small Cap Research is right about the growth of the bioelectronics and neuromodulation markets for relief of chronic and acute pain. EMED is projected to conservatively reach $17 million in volume by 2022, and perhaps as high as $22 million with unit sales of its devices that year reaching 80,000 or 90,000 units, Golman Small Cap Research projected. The FDA cleared WellnessPro Plus device But the Goldman Report is most optimistic about the sales of the to-be-introduced in late 2021 after an anticipated FDA clearance. The analysis likes the combination down payment/subscription revenue model and says its features, such as a remote portal, will drive revenue. The telemedicine-like remote portal will enable physicians and technicians to monitor in real time a remote view of therapy effectiveness.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

2021 And 2022 Projected To Be Boom Years For Electromedical Technologies, Inc. (OTCQB: EMED) As Volume Seen Reaching $17+ Million In Market For The Bioelectronics Industry Treating Chronic And Acute Pain With Its WellnessPro Plus Device And WellnessPlus POD

Projected Volume For EMED In 2022 Could Be $17-$22 Million: Goldman Report

The Goldman report projects that Electromedical Technologies, Inc. (OTCQB: EMED) could sell up to 80,000-90,000 units in 2022 with a physician premium portal feature that could drive 2022 volume as high as $22 million. The goal is to use treatment from the non-invasive devices to evade the $24 billion possibly-addicting opioids pain killer drug market. Medical institutions are looking to alternative therapies to relive chronic and acute pain that do not prescription drugs, which have the side effect of addictions to opioids. It is estimated that the opioid prescription market is $24 billion with 300 million prescriptions for pain killing drugs written annually, the Report said.

Bioelectronics Blocks Nerve Signals Naturally

Bioelectronics blocks nerve signals naturally, far preferred to prescription pharmaceuticals that can have the harmful side effect of opioid addiction. Bioelectronics manipulate the body's nervous system to ignore pain and activate the body's natural pain killers. Anticipating the on-boarding of hundreds of new medical practitioners and distributors, EMED is building up inventory of the devices as it transitions into 2021. 2021 And 2022 Projected To Be Boom Years For Electromedical Technologies, Inc. (OTCQB: EMED) As Volume Seen Reaching $17+ Million In Market For The Bioelectronics Industry Treating Chronic And Acute Pain With Its WellnessPro Plus Device And WellnessPlus POD.

Portal Feature In POD Model Is Seen As Generating Peak Sales

The company has a purchase down payment/subscription payment revenue model which provides recurring revenue for sales of its devices. The upbeat forecast by Goldman SmallCap Research is largely based on prior sales of the FDA cleared Wellness Pro Plus device and forecast of the success of WellnessPlus POD. Analyst Rob Goldman was especially impressed with its telemedicine-like portal feature that permits physicians or technicians to monitor in real time how the wearable POD therapy is delivering relief from acute and chronic pain.

Electromedical Technologies, Inc. (OTCQB: EMED has successfully marketed its non-invasive FDA-cleared WellnessPro Plus(TM) as an alternative treatment to opioid pain killer pharmaceuticals which can be addictive. 2021 And 2022 Projected To Be Boom Years For Electromedical Technologies, Inc. (OTCQB: EMED) As Volume Seen Reaching $17+ Million In Market For The Bioelectronics Industry Treating Chronic And Acute Pain With Its WellnessPro Plus Device And WellnessPlus POD.

Inventory Build Up As Electromedical Technologies, Inc. (OTCQB: EMED) Anticipates More Demand In 2021

For 2021, Matthew Wolfson, CEO, believes that patients who have experienced chronic pain relief from the bioelectronics and electro-modulation delivered by the Wellness Pro Plus devices warrants an inventory build-up. In anticipation of a rush for the product in early 2021, the company has invested $4.2 Million as it has built and paid for a 1,200+ unit inventory in preparation for attracting hundreds more medical practitioners and distributors in 2021.

Goldman Small Cap Research Last Week Set A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED)

Goldman Small Cap Research this week set a $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED), in an Opportunity Research report. The investment analysis projects that the medical device company will reach a volume of $17+ Million in FY2022 and projects EMED will sell some 80,000-90,000 devices in 2022. But both the projected volume and units sold could be even higher. Goldman is encouraged by sales prospects for the Company's WellnessPlus Pod. 2021 And 2022 Projected To Be Boom Years For Electromedical Technologies, Inc. (OTCQB: EMED) As Volume Seen Reaching $17+ Million In Market For The Bioelectronics Industry Treating Chronic And Acute Pain With Its WellnessPro Plus Device And WellnessPlus POD.

The WellnessPlus Pod Seen Debuting In Late 2021, After Anticipated FDA Clearance

Electromedical Technologies, Inc. (OTCQB: EMED) will debut in late 2021 the WellnessPlus POD, a smaller, professional, less costly device that features a special portal for telemedicine-like real time monitoring by physicians. The WellnessPro POD links doctors/technicians and patients with that feature and is less costly, smaller, portable and offers a remote POD portal. The device also provides a unique financial sales structure for the Company, combining a down payment purchase with a recurring monthly subscription services fee.

Source: Stock Market Press

Join Stock Market Press' newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:

Statements in this news release may be "forward-looking statements." Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

comtex tracking

COMTEX_374997282/2718/2020-11-25T10:26:47

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.